論文 - 望月　眞弓

薬局における脂質測定の機会提供の有用性に関する探索的研究

丸山順也,中原佐彩,,富永佳子,多田紀夫,望月眞弓

日本臨床栄養学会雑誌 （日本臨床栄養学会）  42 （ 2 ） 179 - 190 2021年06月

研究論文（学術雑誌）, 共著

Effect of a lever aid on hand strength required for using a handheld inhaler correctly

Nakada H., Aomori T., Mochizuki M.

International Journal of Pharmaceutics （International Journal of Pharmaceutics）  596 2021年03月

ISSN  03785173

　概要を見る

In the treatment of asthma and chronic obstructive pulmonary disease, using a lever aid to improve drug delivery from an inhaler is recommended for patients with poor muscle strength. However, no studies have investigated the effect on hand strength of using a lever aid. Here, we measured hand strength before and after operating a lever aid and tried to predict the required strength. We compared the pinch force required to activate a pressurized metered dose inhaler (pMDI) and a dry powder inhaler as well as the rotational torque required to activate a soft mist inhaler (SMI) before and after attaching a lever aid. We then assessed the correlation between the theoretical and measured pinch force after fitting the lever aid. Use of the lever aid significantly reduced the pinch force required for pMDI operation from 26.13–48.74 N to 4.90–16.87 N. In contrast, using a lever aid significantly reduced the force needed to rotate SMI, although the rotational torque required to operate did not change. There was a significant positive correlation between the theoretical and measured pinch forces required to activate a pMDI fitted with a lever aid. Using a lever aid will increase the number of patients who can use this device.

• Access to Document (DOI)

A cross-sectional study clarifying profiles of patients with diabetes who discontinued pharmacotherapy: reasons and consequences

Tominaga Y., Morisky D.E., Mochizuki M.

BMC Endocrine Disorders （BMC Endocrine Disorders）  21 （ 1 ） 117 - 124 2021年

研究論文（学術雑誌）, 共著, 査読有り

　概要を見る

Background: Although diabetes is one of the fastest increasing diseases in prevalence worldwide and demands significant medical resources, more than half of all patients with diabetes do not achieve the expected target level of blood glucose. As a potential cause of poor glycemic control, insufficient adherence to medication has long been discussed and variably studied. However, dropout from treatment as another plausible cause has not been fully examined. The aim of this study was to clarify profiles of patients with diabetes who discontinued pharmacotherapy (Discont group) by extracting reasons of their decisions and by comparing with those who continued (Cont group) in terms of the related factors to glycemic control. Methods: A cross-sectional, internet-based survey was conducted among Japanese with diabetes registered in a database. A self-administered questionnaire consisting of the 8-item version of the Morisky Medication Adherence Scale (MMAS-8), glycosylated haemoglobin (HbA1c) level, and demographic and disease characteristics was completed by all participants. Reasons for medication discontinuation and resumption were also received retrospectively from participants in the Discont group. To examine the risk of uncontrolled HbA1c, logistic regression analysis was conducted in each group. Results: In the Discont group (148 cases), older age at resumption of pharmacotherapy and current smoking habit increased the probability of uncontrolled HbA1c, whereas in the Cont group (146 cases), a familial history of diabetes and better medication adherence in MMAS-8 scores decreased the probability of uncontrolled HbA1c. A relationship between medication adherence and HbA1c level was seen in the Cont but not in the Discont group. About 70 % of those in the Discont group made their decision to terminate diabetes treatment without consulting physicians and half of them perceived their situations inappropriately. Conclusions: Those who discontinued pharmacotherapy were less adherent to medication than those who did not discontinue. Risk factors for glycemic control also differed between those who discontinued and those who did not. More than one-third of participants with diabetes who discontinued pharmacotherapy had inappropriate perceptions of their disease, which medical professionals should be aware of for better interventions.

• Access to Document (DOI)

Adverse event reports in patients taking psychiatric medication during pregnancy from spontaneous reports in Japan and the United States: An approach using latent class analysis

Anzai T., Takahashi K., Watanabe M., Mochizuki M., Murashima A.

BMC Psychiatry （BMC Psychiatry）  20 （ 1 ）  2020年03月

　概要を見る

© 2020 The Author(s). Background: Little is known regarding the association between adverse events (AEs) and psychiatric medications administered to pregnant women in clinical trials during the pre-marketing period. This study analyzes reports of AE association with psychiatric medication administrated during pregnancy using post-marketing spontaneous reports of AE from the Japanese Adverse Drug Event Report (JADER) database and Food and Drug Administration Adverse Event Reporting System in the United States (FAERS-US). Methods: We summarized AE reports of psychiatric medication administrated during pregnancy by comparing data obtained from JADER and FAERS-US databases with medication patterns determined as classes via latent class analysis. The odds ratios (ORs) of AE reports categorized into system organ classes in which each class was compared with those without psychiatric medications. Results: The proportions of AE reports under psychiatric medication in pregnancy among all AE reports were 22.0% and 16.6% in JADER and FAERS-US, respectively. The 10,389 reports of psychiatric medication during pregnancy were classified into 11 classes. The proportion of patients receiving four or more psychiatric drugs in JADER was larger than that in FAERS-US. The maximum number of reports in combinations of AE and medication pattern in JADER was 169, for 'general disorders and administration site conditions' from the class of four or more medications (OR = 9.1), while that in FAERS-US was 1,654, for 'injury, poisoning, and procedural complications' from the class of single psychiatric medication (OR = 2.8). Conclusions: The main AE reports and associated AE differed depending on medication patterns in pregnant women taking psychiatric medication. This study may provide a prediction of AEs that are likely to be reported with each medication pattern. Our findings of the association between AE reports and medication patterns could help improve the administration of psychiatric medications during pregnancy, though further research on additional datasets is needed to clarify these results.

• Access to Document (DOI)

Factors contributing to the systemic clearance of infliximab with long-term administration in Japanese patients with Crohn's disease: Analysis using population pharmacokinetics


Matsuoka K., Hamada S., Shimizu M., Nanki K., Mizuno S., Kiyohara H., Arai M., Sugimoto S., Iwao Y., Ogata H., Hisamatsu T., Nagauma M., Kanai T., Mochizuki M., Hashiguchi M.

International journal of clinical pharmacology and therapeutics （International journal of clinical pharmacology and therapeutics）  58 （ 2 ） 89 - 102 2020年02月

ISSN  09461965

　概要を見る

OBJECTIVE: Crohn's disease (CD) is a chronic inflammatory gastrointestinal disease with repeated cycles of exacerbation and remission. Infliximab (IFX), a chimeric anti-TNF-α monoclonal antibody, has been widely used for the treatment of CD. However, no study in Japanese CD patients receiving continuous IFX for more than 1 year has been reported. To avoid therapeutic failure during long-term administration in Japanese CD patients, we evaluated the variable factors of IFX pharmacokinetics and the optimal trough IFX concentration at 8 weeks after administration. MATERIALS AND METHODS: Population pharmacokinetic (PPK) analysis was performed using the nonlinear mixed-effect model based on the IFX serum concentration in 832 samples from 121 patients. A one-compartment model was used to examine interindividual variability in the systemic clearance (CL) of intravenously administered IFX. RESULTS: PPK estimates (estimated value, RSE%) were total clearance (CL: 0.018 L/h, 9.1) and volumes of distribution (Vd: 7.35 L, 12.0). Interindividual variability for CL and Vd of 0.11 and 0.16, respectively, was found. Body weight, antibody to IFX (ATI), and albumin level were factors affecting the IFX CL. IFX CL was greater in the ATI-positive than in the ATI-negative group. CL was also greater in nonremission patients. There was a significant association between the predicted serum IFX trough concentration at 8 weeks and therapeutic response with long-term continuous administration (p < 0.05), with a higher concentration at 8 weeks seen in the remission group. CONCLUSION: Using these variables including body weight, ATI, and albumin level, the IFX dose could be calculated for individual CD patients to achieve the optimal therapeutic range.

• Access to Document (DOI)

Exploration of education and research on drug informatics

Mochizuki M.

Yakugaku Zasshi （Yakugaku Zasshi）  140 （ 4 ） 543 - 554 2020年

ISSN  00316903

　概要を見る

© 2020 The Pharmaceutical Society of Japan I have been exploring methods for education and research on drug information for 43 years. There are various approaches to drug informatics research, which include collecting, evaluating, and analyzing information to solve drug related problems, sometimes producing new information from experiments and clinical research. All are based on information science. Drug informatics is information science from the viewpoint of pharmaceuticals. In addition to basic pharmacology, knowledge and skills such as epidemiology, data science, computer science, mathematical statistics, and communication studies are indispensable for the development of drug informatics.

• Access to Document (DOI)

Long-term effect of NUDT15 R139C on hematologic indices in inflammatory bowel disease patients treated with thiopurine

Akiyama S., Matsuoka K., Fukuda K., Hamada S., Shimizu M., Nanki K., Mizuno S., Kiyohara H., Arai M., Sugimoto S., Iwao Y., Ogata H., Hisamatsu T., Naganuma M., Motobayashi M., Suzuki K., Takenaka K., Fujii T., Saito E., Nagahori M., Ohtsuka K., Mochizuki M., Watanabe M., Hashiguchi M., Kanai T.

Journal of Gastroenterology and Hepatology (Australia) （Journal of Gastroenterology and Hepatology (Australia)）  34 （ 10 ） 1751 - 1757 2019年10月

ISSN  08159319

　概要を見る

© 2019 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd Background and Aim: A missense variant of the nucleoside diphosphate-linked moiety X-type motif 15 (NUDT15) gene (R139C) predisposes Asian patients with inflammatory bowel disease (IBD) to thiopurine-induced leukopenia. This study evaluates the long-term effect of NUDT15 R139C heterozygosity on hematological parameters during thiopurine administration. Methods: We enrolled 83 Japanese IBD patients who were on anti-tumor necrosis factor-α agents and had used thiopurine. NUDT15 R139C was genotyped by polymerase chain reaction. We retrospectively reviewed patient clinical charts to collect data on white blood cell (WBC) count, mean corpuscular volume (MCV), hemoglobin, and platelet count during the 24 months following thiopurine initiation. Results: The included patients had either Crohn's disease (54; 65.1%) or ulcerative colitis (29; 34.9%). Genotyping of NUDT15 R139C identified 62 patients (74.7%) of genotype C/C and 21 (25.3%) of genotype C/T. The median dose of thiopurine was lower in the C/T group than in the C/C group after starting thiopurine. At 6 months, the mean WBC count of the C/T group became significantly lower than that of the C/C group (P = 0.008) and remained lower through the 24 months. The C/T group developed grade 2–4 leukopenia by 6 months, which persisted through 12–24 months. The mean MCV in the C/T group became higher than that of the C/C group after 3 months. Conclusions: NUDT15 R139C heterozygosity affected the WBC count and MCV for 24 months after thiopurine administration. Our results indicate that careful monitoring of leukopenia and dose adjustment are necessary throughout treatment in IBD patients heterozygous for the NUDT15 R139C.

• Access to Document (DOI)

Positive predictive value of ICD-10 codes for acute myocardial infarction in Japan: A validation study at a single center

Ando T., Ooba N., Mochizuki M., Koide D., Kimura K., Lee S., Setoguchi S., Kubota K.

BMC Health Services Research （BMC Health Services Research）  18 （ 1 ）  2018年11月

　概要を見る

© 2018 The Author(s). Background: In Japan, several large healthcare databases have become available for research since the early 2000's. However, validation studies to examine the accuracy of these databases remain scarce. We conducted a validation study in order to estimate the positive predictive value (PPV) of local or ICD-10 codes for acute myocardial infarction (AMI) in Japanese claims. In particular, we examined whether the PPV differs between claims in the Diagnosis Procedure Combination case mix scheme (DPC claims) and in non-DPC claims. Methods: We selected a random sample of 200 patients from all patients hospitalized at a large tertiary-care university hospital between January 1, 2009 and December 31, 2011 who had an inpatient claim assigned a local or ICD-10 code for AMI. We used a standardized data abstraction form to collect the relevant information from an electronic medical records system. Abstracted information was then categorized by a single cardiologist as being either definite or not having AMI. Results: In a random sample of 200 patients, the average age was 67.7 years and the proportion of males was 78.0%. The PPV of the local or ICD-10 code for AMI was 82.5% in this sample of 200 patients. Further, of 178 patients who had an ICD-10 code for AMI based on any of the 7 types of condition codes in the DPC claims, the PPV was 89.3%, whereas of the 161 patients who had an ICD-10 code for AMI based on any of 3 major types of condition codes in the DPC claims, the PPV was 93.8%. Conclusion: The PPV of the local or ICD-10 code for AMI was high for inpatient claims in Japan. The PPV was even higher for the ICD-10 code for AMI for those patients who received AMI care through the DPC case mix scheme. The current study was conducted in a single center, suggesting that a multi-center study involving different types of hospitals is needed in the future. The accuracy of condition codes for DPC claims in Japan may also be worth examining for conditions other than AMI such as stroke.

• Access to Document (DOI)

Factors predicting the therapeutic response to infliximab during maintenance therapy in Japanese patients with Crohn's disease

Matsuoka K., Hamada S., Shimizu M., Nanki K., Mizuno S., Kiyohara H., Arai M., Sugimoto S., Iwao Y., Ogata H., Hisamatsu T., Naganuma M., Kanai T., Mochizuki M., Hashiguchi M.

PLoS ONE （PLoS ONE）  13 （ 10 ）  2018年10月

研究論文（学術雑誌）, 共著, 査読有り,  ISSN  1932-6203

　概要を見る

© 2018 Hsieh et al. Since anti-tumor necrosis factor (TNF)-α agents (TNF-α inhibitors) induce both clinical response and remission in patients with moderate to severe inflammatory bowel disease (IBD), the use of anti-TNF therapies has fundamentally changed the approach to treatment for patients with IBD. Infliximab (IFX) is a TNF-α inhibitor approved for the induction and remission of Crohn's disease (CD). However, even among patients who initially demonstrate a clinical response to IFX therapy, secondary loss of response occurs, although the reason remains unknown. We therefore investigated predictive factors associated with the response to IFX in long-term maintenance treatment in Japanese CD patients. Eight types of single-nucleotide polymorphisms (SNPs) were investigated using the real-time PCR method, and patient characteristics were collected from the electronic medical records. The Crohn's Disease Activity Index criteria were used as the response to IFX therapy. The observation period was 1 year after IFX had been administered for more than 1 year. Associations between the IFX response and patient characteristics were evaluated using the multivariate logistic regression model. We studied 121 unrelated adult Japanese with CD treated for more than 1 year with IFX as outpatients at Keio University Hospital from November 1, 2014 to November 30, 2015. Among them, 71 were classified as in remisson. In multivariate analysis, patients with the TNF-α 857C>T C/C genotype, shorter disease duration, without double dosing, and combination treatment with an immunomodulator had higher remisson rates than those with the C/T or T/T genotype, longer disease duration, with double dosing, and no combination treatment with an immunomodulator. The response to IFX in Japanese CD patients may therefore be predicted by these 4 characteristics in actual clinical practice.

• Access to Document (DOI)

Factors predicting the therapeutic response to methotrexate in Japanese patients with rheumatoid arthritis: A hospital-based cohort study

Hakamata J., Kaneko Y., Shimizu M., Yamaoka K., Maruyama J., Takeuchi T., Mochizuki M., Hashiguchi M.

Biological and Pharmaceutical Bulletin （Biological and Pharmaceutical Bulletin）  41 （ 9 ） 1414 - 1422 2018年09月

研究論文（学術雑誌）, 共著, 査読有り,  ISSN  0918-6158

　概要を見る

© 2018 The Pharmaceutical Society of Japan. Methotrexate (MTX) is used widely as a first-line drug for the treatment of rheumatoid arthritis (RA) worldwide. There are large interindividual differences in the therapeutic response to MTX, but it is not known which factors influence them. We therefore investigated predictive factors associated with the therapeutic response to MTX in a hospital-based cohort study. Japanese adult RA outpatients prescribed MTX were enrolled and their characteristics were collected from the electronic medical records. The European League Against Rheumatism (EULAR) response criteria were used as the response to MTX therapy. The observation period was 1 year after beginning MTX administration. Sixteen types of single-nucleotide polymorphisms were investigated using the real-time PCR method. Associations between the MTX response and patient characteristics were evaluated using the multivariate logistic regression model. Among 70 Japanese adult RA outpatients, 52 were classified as MTX responders. In multivariate analysis, patients with the solute carrier family 19 member 1 (SLC19A1) 80G>A A/A genotype had a better response than those with the A/G or G/G genotype, and patients with the C allele of γ-glutamyl hydrolase (GGH) 16T>C had a better response than those with the T/T genotype.This study showed that the therapeutic response to MTX in Japanese RA patients was associated with the genetic polymorphisms of SLC19A1 80G>A and GGH 16T>C in actual clinical practice.

• Access to Document (DOI)

Extraction and standardization of patient complaints from electronic medication histories for pharmacovigilance: Natural language processing analysis in Japanese

Usui M., Aramaki E., Iwao T., Wakamiya S., Sakamoto T., Mochizuki M.

Journal of Medical Internet Research （Journal of Medical Internet Research）  20 （ 9 ）  2018年09月

　概要を見る

© Misa Usui, Eiji Aramaki, Tomohide Iwao, Shoko Wakamiya, Tohru Sakamoto, Mayumi Mochizuki. Originally published in JMIR Medical Informatics (http://medinform.jmir.org), 27.09.2018. This is an open-access article distributed under the terms of the Creative Commons Attribution License. Background: Despite the growing number of studies using natural language processing for pharmacovigilance, there are few reports on manipulating free text patient information in Japanese. Objective: This study aimed to establish a method of extracting and standardizing patient complaints from electronic medication histories accumulated in a Japanese community pharmacy for the detection of possible adverse drug event (ADE) signals. Methods: Subjective information included in electronic medication history data provided by a Japanese pharmacy operating in Hiroshima, Japan from September 1, 2015 to August 31, 2016, was used as patients' complaints. We formulated search rules based on morphological analysis and daily (nonmedical) speech and developed a system that automatically executes the search rules and annotates free text data with International Classification of Diseases, Tenth Revision (ICD-10) codes. The performance of the system was evaluated through comparisons with data manually annotated by health care workers for a data set of 5000 complaints. Results: Of 5000 complaints, the system annotated 2236 complaints with ICD-10 codes, whereas health care workers annotated 2348 statements. There was a match in the annotation of 1480 complaints between the system and manual work. System performance was .66 regarding precision, .63 in recall, and .65 for the F-measure. Conclusions: Our results suggest that the system may be helpful in extracting and standardizing patients' speech related to symptoms from massive amounts of free text data, replacing manual work. After improving the extraction accuracy, we expect to utilize this system to detect signals of possible ADEs from patients' complaints in the future.

• Access to Document (DOI)

Exploratory evaluation of a commercially available Japanese medical record database as an external control for comparative clinical trials in new drug development: Amyotrophic lateral sclerosis

Fukamachi S, Hashiguchi M, Takahashi K, Mochizuki M

Neurology and Clinical Neuroscience （Japanese Society of Neurology and John Wiley & Sons Australia, Ltd）  6   94 - 99 2018年05月

研究論文（学術雑誌）, 共著, 査読有り

• Access to Document (DOI)

OTC医薬品添付文書におけるピクトグラム表示の試み

朴 京子, 小山 慎一, 山下 純, 望月 眞弓, 日比野 治雄

医薬品情報学 （日本医薬品情報学会）  20 （ 1 ） 20 - 28 2018年05月

研究論文（学術雑誌）, 共著, 査読有り

Risk factors for rhabdomyolysis with HMG-CoA reductase inhibitors identified using a postmarketing surveillance database in Japan
.

Hashiguchi M, Hakamata J, Shimizu M, Maruyama J, Shiga T, Mochizuki M.

Int J Clin Pharmacol Ther. 2018年04月

研究論文（学術雑誌）, 共著, 査読有り

• Access to Document (DOI)

Risk factors for abnormal hepatic enzyme elevation by methotrexate treatment in patients with rheumatoid arthritis: A hospital based-cohort study

Hakamata J., Hashiguchi M., Kaneko Y., Yamaoka K., Shimizu M., Maruyama J., Takeuchi T., Mochizuki M.

Modern Rheumatology （Modern Rheumatology）  2 （ 4 ） 1 - 10 2018年01月

研究論文（学術雑誌）, 共著,  ISSN  14397595

　概要を見る

© 2017, © 2017 Japan College of Rheumatology. Objectives: Methotrexate (MTX) is used as first-line treatment of rheumatoid arthritis (RA) worldwide. Large interindividual differences in MTX effectiveness and safety occur, and the most frequent adverse reaction is hepatotoxicity, although the main cause remains unknown. We investigated factors associated with MTX-induced hepatic enzyme elevation in a hospital-based cohort study. Methods: Study participants were 114 Japanese adult RA outpatients prescribed MTX. Sixteen types of single-nucleotide polymorphisms were investigated using real-time PCR. Patient characteristics were collected from the electronic medical records. The onset of MTX-induced abnormal hepatic enzyme elevation was defined according to deviation from normal liver enzyme reference values during treatment. The observation period was 1 year after beginning MTX. Associations between MTX-induced hepatic enzyme elevation and patient characteristics were evaluated using the multivariate logistic regression model. Results: Thirty-two patients experienced MTX-induced abnormal hepatic enzyme elevation. In multivariate analysis, MTX dosage, estimated glomerular filtration rate (eGFR), and genetic polymorphisms of ABCB1 3435C>T and ATIC 347C>G were associated with abnormal hepatic enzyme elevation. Conclusions: MTX-induced abnormal hepatic enzyme elevation in Japanese RA patients was associated with dosage and eGFR as nongenetic factors, and with ABCB1 3435C>T and ATIC 347C>G as genetic factors in this hospital-based cohort study.

• Access to Document (DOI)

Possible associations of personality traits representing harm avoidance and self-directedness with medication adherence in Japanese patients with type 2 diabetes.

Y. Tominaga, T. Aomori, T. Hayakawa, N. Kijima, D.E. Morisky, K. Takahashi, M. Mochizuki.

Journal of Pharmaceutical Health Care and Sciences. 4   16 2018年

研究論文（学術雑誌）, 共著, 査読有り

Relationship between medication adherence and glycemic control in Japanese patients with type 2 diabetes

Tominaga Y., Aomori T., Hayakawa T., Morisky D., Takahashi K., Mochizuki M.

Pharmazie （Pharmazie）  73 （ 10 ） 609 - 612 2018年

ISSN  00317144

　概要を見る

© 2018 Govi-Verlag Pharmazeutischer Verlag GmbH. All rights reserved. A cross-sectional survey of 358 patients was conducted among type 2 diabetes patients recruited at medical institutions or via an online research company. Medication adherence was measured using the 8-item Morisky Medication Adherence Scale (MMAS-8). Univariate and multivariate regression analyses of glycosylated hemoglobin (HbA 1c ) were performed in addition to assessing demographic and disease characteristics and MMAS-8. In conclusion, medication adherence as measured by the MMAS-8 score independently contributes to altering the HbA 1c level in the range of 1.12 %. The number of medications prescribed and insulin use are also related to HbA 1c .

• Access to Document (DOI)

Risk factors for rhabdomyolysis with HMG-CoA reductase inhibitors identified using a postmarketing surveillance database in Japan

Hashiguchi M., Hakamata J., Shimizu M., Maruyama J., Shiga T., Mochizuki M.

International Journal of Clinical Pharmacology and Therapeutics （International Journal of Clinical Pharmacology and Therapeutics）  56 （ 7 ） 310 - 320 2018年

ISSN  09461965

　概要を見る

©2018 Dustri-Verlag Dr. K. Feistle. Objective: To investigate quantitatively the risk factors for rhabdomyolysis or related symptoms associated with HMG-CoA reductase inhibitors (statins), we used the lipid-lowering drug database (32,157 patients) developed by the RAD-AR Council, Japan, based on the postmarketing surveillance (PMS) data of pharmaceutical companies to perform a nested case-control study. Materials and methods: Of 26,849 patients taking statins, the case group was composed of 51 patients who experienced rhabdomyolysis or related symptoms while taking statins, and the control group was 1,020 patients randomly selected from patients who did not experience rhabdomyolysis or related symptoms while taking statins. Relevant factors that can be extracted from the database were: sex, age, body mass index (BMI), statin use duration, complications, concomitant medication, and clinical laboratory test values. Results: Among those taking statins, 51 experienced rhabdomyolysis or related symptoms. Factors differing significantly between the two groups by univariate analysis were age, duration of statin intake, combination drugs (Ca antagonists, angiotensin II receptor blocker (ARB), cardiac drugs, benzodiazepines, mucoprotective drugs, insulin, α-glucosidase inhibitors), clinical laboratory results (high-density lipoprotein cholesterol (HDL-C), aspartate aminotransferase, alkaline phosphatase, total bilirubin), and complications (alcoholic hepatitis). Conditional multivariate logistic analysis of these factors yielded adjusted/odds ratios of 8.82 for the concomitant administration of an ARB and 3.45 for increased AST and 3.20 for increased total bilirubin levels. Conclusion: Risk factors for rhabdomyolysis or related symptoms associated with taking statins were combination with ARB and increases in AST or total bilirubin levels.

• Access to Document (DOI)

Risk factors for hyperuricemia with HMG-CoA reductase inhibitors using a postmarketing surveillance database in Japan

Hashiguchi M., Hakamata J., Shimizu M., Maruyama J., Shiga T., Mochizuki M.

Japanese Journal of Clinical Pharmacology and Therapeutics （Japanese Journal of Clinical Pharmacology and Therapeutics）  49 （ 4 ） 145 - 150 2018年

ISSN  03881601

　概要を見る

Copyright: © 2018 the Japanese Society of Clinical Pharmacology and Therapeutics(JSCPT) Background: Little is known about whether HMG-CoA reductase inhibitor(statin)treatment exerts an adverse effect on serum levels of uric acid. It remains unknown whether statin use is associated with an increased risk of hyperuricemia. The purpose of this study was to identify the risk factors for developing hyperuricemia or blood uric acid elevation associated with statin use utilizing the Japanese RAD-AR postmarketing surveillance database. Methods: We performed a nested case-control study using a postmarketing surveillance database in Japan. The database cohort included 26,914 cases of statin use in patients with hyperlipidemia. Participants received at least one type of statin, had a clear medication history of statin use, and no complication of hyperuricemia. Cases were defined as onset of hyperuricemia or blood uric acid elevation during statin intake. For each case, 20 controls were randomly selected and matched by time-point. The factors associated with an increased risk of hyperuricemia or blood uric acid elevation during statin intake examined included sex, age, body mass index, statin use duration, complications, concomitant medications, and clinical laboratory test values. Statin-associated hyperuricemia or blood uric acid elevation was identified based on abnormal elevation of blood uric acid concentrations beyond the reference range. Results: A total of 20,783 patients met the inclusion criteria, of whom 23 were in the case group. Two complicating factors, sympathetic inhibitory antihypertensive drugs (adjusted odds ratio［OR］: 4.22)and triglyceride level(adjusted OR: 2.48), were extracted for onset of hyperuricemia or blood uric acid elevation. Conclusion: This study suggested that the onset of hyperuricemia or blood uric acid elevation might increase with statin use in patients with complications of hypertriglyceridemia and concomitant administration of sympathetic inhibitory antihypertensive drugs.

• Access to Document (DOI)

Effect of everolimus on the glucose metabolic pathway in mouse skeletal muscle cells (C2C12)

Kayoko Yoshida, Chiyo K. Imamura ,Kanako Hara ,Mayumi Mochizuki, Yusuke Tanigawara

Metabolomics （Cross Mard）  13   98 2017年07月

研究論文（学術雑誌）, 共著, 査読有り

• Access to Document (DOI)

Development and evaluation of an overseas clinical rotation program for undergraduate pharmacy students in Japan.

Ohtani H, Mitsui R, Akiyoshi T, Imaoka A, Abe Y, Kanke M, Nakamura T, Foster P, Mochizuki M.

Curr Pharm Teach Learn. 9 （ 3 ） 452 - 459 2017年05月

研究論文（学術雑誌）, 共著, 査読有り

• Access to Document (DOI)

Ethnic and gender differences in genetic polymorphisms of tumor necrosis factor (TNF)-α in a Japanese population.

Hakamata　J, Hashiguchi M, Tsuru T, Tanaka T, Irie S, Shimizu M, Mochizuki M.

Jpn J Clin Pharmacol Ther 48 （ (2) ） 21 - 26 2017年

研究論文（学術雑誌）, 査読有り

災害時に有効活用できるOTC医薬品

鹿村恵明、田中愛佳、根岸健一、下平秀夫、若林進、塚原俊夫、野村香織、出石啓治、宮崎長一郎、望月眞弓、上村直樹

医薬品情報学 （日本医薬品情報学会）  18 （ 4 ） 242 - 250 2017年

研究論文（学術雑誌）, 査読有り

生活習慣病患者のスイッチOTC医薬品に対する意識調査

成井 浩二, 石川 あゆみ, 小原 安希子, 鈴木 悠希, 岡本 有史, 富澤 崇, 望月 眞弓, 渡辺 謹三

社会薬学 （日本社会薬学会）  35 （ 2 ） 62 - 68 2016年12月

研究論文（学術雑誌）, 査読有り

Sex Differences in mRNA Expression of Reduced Folate Carrier-1, Folypolyformyl Glutamate Synthase, and γ-Glutamyl Hydrolase in a Healthy Japanese Population

Hashiguchi Masayuki, Tanaka Takanori, Shimizu Mikiko, Tsuru Tomomi, Chiyoda Takeshi, Miyawaki Kumika, Irie Shin, Takeuchi Osamu, Hakamata Jun, Mochizuki Mayumi

Journal of Clinical Pharmacology 56 （ 12 ） 1563 - 1569 2016年12月

研究論文（学術雑誌）, 共著, 査読有り,  ISSN  0091-2700

　概要を見る

<p>Sex differences in the prevalence of autoimmune diseases such as rheumatoid arthritis (RA) are well known, but little is known about those differences in relation to therapeutic response. Reduced folate carrier-1 (RFC-1), folypolyformyl glutamate synthase (FPGS), and γ-glutamyl hydrolase (GGH) are important transporters and enzymes that convert methotrexate (MTX) in the body. This study investigated the sex differences in mRNA expression of RFC-1, FPGS, and GGH in 190 unrelated healthy Japanese people. The genotypes and mRNA expression were determined using the real-time PCR method. Significant differences between men and women were observed in RFC-1, FPGS, and GGH mRNA expression. The mRNA expression of FPGS and GGH was greater in women than that in men, but the expression of RFC-1 was less in the former than the latter. In stratified analysis by genotype, significant differences in sex-specific mRNA expression were observed in G/G of FPGS, C/C of GGH 452, and C/C of GGH -401. All showed greater mRNA expression in women than in men. In the 5 single-nucleotide polymorphisms RFC-1 80G&gt;A, RFC-1 -43T&gt;C, FPGS 1994G&gt;A, GGH 452C&gt;T, and GGH -401C&gt;T examined, the FPGS 1994 G/G (1.46-fold), GGH 452 C/C (2.16-fold), and GGH -401 C/C (2.68-fold) genotypes showed significantly higher mRNA expression in women than in men. Healthy Japanese adults in this study showed sex-specific differences in mRNA expression that differed among RFC-1, FPGS, and GGH. Therefore, the relationship between genetic polymorphisms and mRNA expression including sex differences might contribute to the variation in the efficacy/toxicity of MTX in patients with RA.</p>

• Access to Document (DOI)

Possible involvement of distinct phylogenetic clusters of HIV-1 variants in the discrepancies between coreceptor tropism predictions based on viral RNA and proviral DNA.

Kotani H, Sudo K, Hasegawa N, Fujiwara H, Hayakawa T, Iketani O, Yamaguchi M, Mochizuki M, Iwata S, Kato S.

J Pharm Health Care Sci （Bio Med Central）  2   31 2016年11月

研究論文（学術雑誌）, 共著, 査読有り

• Access to Document (DOI)

セルフメディケーションにおける薬剤師と需要者間の双方向性コミュニケーションの実現に向けた質問紙調査

高橋 由佳, 石井 伊都子, 望月 眞弓, 山下 純

医薬品情報学 （日本医薬品情報学会）  18 （ 3 ） 160 - 171 2016年11月

研究論文（学術雑誌）, 共著, 査読有り

Application of indirect comparison to the drug development process: forecasting direct comparison study results

Kunitomi T, Hashiguchi M, Mochizuki M.

J Clin Pharmacol 56 （ 9 ） 1165 - 1170 2016年09月

研究論文（学術雑誌）, 査読有り

• Access to Document (DOI)

Pregnancy outcomes after exposure to tocilizumab: A retrospective analysis of 61 patients in Japan

Nakajima K, Watanabe O, Mochizuki M, Nakasone A, Ishizuka N, Murashima A

Mod Rheumatol 26 （ 5 ） 667 - 671 2016年09月

研究論文（学術雑誌）, 査読有り

• Access to Document (DOI)

Socioeconomic Impacts of Policy on Rx-to-OTC Switch to Prescription of Ethical Drugs in Japan

Shimazaki, Keisuke, Takano, Yuma, Matsushima, Yukiko, Mochizuki, Mayumi, Takahashi, Kunihiko, Urushihara, Hisashi

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 25   349 - 349 2016年08月

研究論文（学術雑誌）,  ISSN  1053-8569

Preliminary study for predicting better methotrexate efficacy in Japanese patients with rheumatoid arthritis.

Hashiguchi M, Tsuru T, Miyawaki K, Suzaki M, Hakamata J, Shimizu M, Irie S, Mochizuki M.

J Pharm Health Care Sci. （Bio Med Central）  2   13 2016年06月

研究論文（学術雑誌）, 共著, 査読有り

• Access to Document (DOI)

Genetic polymorphisms of enzyme proteins and transporters related to methotrexate response and pharmacokinetics in a Japanese population.

Hashiguchi M, Shimizu M, Hakamata J, Tsuru T, Tanaka T, Suzaki M, Miyawaki K, Chiyoda T, Takeuchi O, Hiratsuka J, Irie S, Maruyama J, Mochizuki M.

J Pharm Health Care Sci 9 （ 2 ） 35 2016年

研究論文（学術雑誌）, 査読有り

Preliminary study for predicting better methotrexate efficacy in Japanese patients with rheumatoid arthritis.

Hashiguchi M, Tsuru T, Miyawaki K, Suzaki M, Hakamata J, Shimizu M, Irie S, Mochizuki M.

J Pharm Health Care Sci 7 （ 2 ） 13 2016年

研究論文（学術雑誌）, 査読有り

Factors Affecting the Timing of Signal Detection of Adverse Drug Reactions

Masayuki Hashiguchi, Shungo Imai, Keiko Uehara, Junya Maruyama, Mikiko Shimizu, Mayumi Mochizuki

PLoS ONE 10 （ 2 ） e0144263 2015年12月

研究論文（学術雑誌）, 共著, 査読有り

• Access to Document (DOI)

Student exchange program between Keio University and US universities for international clinical practice

Ohtani, Hisakazu, Foster, Patrick, Kanke, Motoko, Nakamura, Tomonori, Abe, Yoshihiro, Mochizuki, Mayumi

PHARMACOTHERAPY 35 （ 11 ） E245 - E245 2015年11月

研究論文（学術雑誌）,  ISSN  0277-0008

Meta-Analysis: Effects of Probiotic Supplementation on Lipid Profiles in Normal to Mildly Hypercholesterolemic Individuals

Mikiko Shimizu, Masayuki Hashiguchi, Tsuyoshi Shiga, Hiro-omi Tamura, Mayumi Mochizuki

PLoS ONE 10 （ 10 ） e0139795 2015年10月

研究論文（学術雑誌）, 共著, 査読有り

• Access to Document (DOI)

常用量以下の曝露量における全身性副作用の用量依存性の推定

三井 梨恵子, 秋好 健志, 今岡 鮎子, 望月 眞弓, 大谷 壽一

医薬品情報学 17 （ 2 ） 77 - 86 2015年08月

研究論文（学術雑誌）, 査読有り

Effect of database profile variation on drug safety assessment: an analysis of spontaneous adverse event reports of Japanese cases

Kaori Nomura, Kunihiko Takahashi, Yasushi Hinomura, Genta Kawaguchi, Yasuyuki Matsushita, Hiroko Marui, Tatsuhiko Anzai, Masayuki Hashiguchi, Mayumi Mochizuki

Drug Design, Development and Therapy （Dovepress）  9   3031 - 3041 2015年06月

研究論文（学術雑誌）, 共著, 査読有り

Meta-analysis of the efficacy and safety of Ginkgo biloba extract for the treatment of dementia

Masayuki Hashiguchi, Yuriko Ohta, Mikiko Shimizu, Junya Maruyama1 and Mayumi Mochizuki

Journal of Pharmaceutical Health Care and Sciences （BioMed Central）  1   14 2015年05月

研究論文（学術雑誌）, 共著, 査読有り

• Access to Document (DOI)

薬学臨床系教員の現状に関するアンケート調査(第2報)

野田 幸裕, 矢野 育子, 青山 隆夫, 渡邊 美智留, 今田 愛也, 中村 均, 松下 良, 森田 邦彦, 三宅 勝志, 瀬尾 量, 上村 直樹, 富岡 佳久, 木津 純子, 望月 眞弓

医療薬学 41 （ 4 ） 223 - 235 2015年04月

研究論文（学術雑誌）, 査読有り

Effect of Common Comparators in Indirect Comparison Analysis of the Effectiveness of Different Inhaled Corticosteroids in the Treatment of Asthma

Taro Kunitomi , Masayuki Hashiguchi, Mayumi Mochizuki

PLoS ONE （Public Library of Science）  10 （ 3 ） e0120836 2015年03月

研究論文（学術雑誌）, 共著, 査読有り

• Access to Document (DOI)

Quantitation of pilsicainide in microscale samples of human biological fluids using liquid chromatography-tandem mass spectrometry.

Shimizu M, Hashiguchi M, Shiga T, Nakamura K, Tamura H, Mochizuki M.

J Chromatography 985   172 - 179 2015年03月

研究論文（学術雑誌）, 共著, 査読有り

個別薬剤の医薬品情報に関する自己学習教材の開発と教員、学生のアンケート

福井 悠美, 大津 史子, 後藤 伸之, 小川 雅史, 太田 隆文, 黒澤 菜穂子, 望月 眞弓, 山田 安彦

医薬品情報学 16 （ 4 ） 193 - 200 2015年02月

研究論文（学術雑誌）, 査読有り

実務実習での医薬品情報に関する学びの実態調査及びモデル教材の開発と評価

前仲 亮宏, 大津 史子, 後藤 伸之, 小川 雅史, 太田 隆文, 黒澤 菜穂子, 望月 眞弓, 山田 安彦

医薬品情報学 16 （ 4 ） 157 - 168 2015年02月

研究論文（学術雑誌）, 査読有り

Expected value of the additional state in evaluating the method of quantification and uncertainty of additional states in an analytical model of grade I hypertension.

Uchikura T, Kobayashi M, Hashiguchi M, Mochizuki M.

Journal of Pharmaceutical Health Care and Sciences. 1 （ 3 ） 1 - 7 2015年01月

研究論文（学術雑誌）, 共著, 査読有り

Patients views and experiences in online reporting adverse drug reactions: findings of a national pilot study in Japan.

Yamamoto M, Kubota K, Okazaki M, Dobashi A, Hashiguchi H, Doi H, Suka M, Mochizuki M.

Patient Preference and Adherence 9   173 - 184 2015年

研究論文（学術雑誌）, 共著, 査読有り

日本における適正な安全性監視計画作成のためのタスクフォース」報告書　よりよい医薬品安全性監視計画作成とチェックリスト

久保田 潔, 青木 事成, 漆原 尚巳, 鍵村 達夫, 景山 茂, 小出 大介, 古閑 晃, 佐藤 嗣道, 中村 敏明, 中島 研, 畑中 直也, 平河 武, 宮川 功, 望月 眞弓

薬剤疫学 19 （ 1 ） 57 - 75 2014年06月

研究論文（学術雑誌）, 査読有り

Indirect comparison analysis of efficacy and safety between olanzapine and aripiprazole for schizophrenia.

Kunitomi T, Hashiguchi M, Mochizuki M*.

British Journal of Clinical Pharmacology 76(10)   767 - 776 2014年05月

研究論文（学術雑誌）, 共著, 査読有り

スイッチOTC医薬品に対する一般生活者の意識調査.

成井 浩二, 望月 眞弓, 渡辺 謹三.

医療薬学    Page726-732 2013年12月

研究論文（学術雑誌）, 共著, 査読有り

An Assessment of How the Outputs from Signal Detection Can Be Effected by Variation of Database Profile by Analysing Adverse Events Reports of FDA and PMDA Received in 2010

Nomura, Kaori, Takahashi, Kunihiko, Hinomura, Yasushi, Kawaguchi, Genta, Matsushita, Yasuyuki, Marui, Hiroko, Anzai, Tatsuhiko, Hashiguchi, Masayuki, Mochizuki, Mayumi

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 22   301 - 301 2013年10月

研究論文（学術雑誌）,  ISSN  1053-8569

Temporal relationship between multiple drugs and multiple events in patient reports on adverse drug reactions: findings in a pilot study in Japan.

Kubota K, Okazaki M, Dobashi A, Yamamoto M, Hashiguchi M, Horie A, Inagaki A, Kikuchi T, Mochizuki M.

Pharmacoepidemiology and Drug Safety 22   1134-1137 2013年10月

研究論文（学術雑誌）, 共著, 査読有り

「医薬品に関する教育」が変える日本の医療

望月 眞弓

YAKUGAKU ZASSHI （日本薬学会）  133 （ 12 ） 1315 - 1318 2013年08月

研究論文（学術雑誌）, 単著, 査読有り

Lack of pharmacokinetic interaction between pilsicainide and rifampicin in healthy volunteers.

Shiga T*, Hashiguchi H, Nakamura K, Shimizu M, Shimizu K, Suzuki A, Mochizuki M, Hagiwara N.

Jpn J Clin Pharmacol Ther 44(4)   301-305 2013年08月

研究論文（学術雑誌）, 共著, 査読有り

Relationship between genetic polymorphism and mRNA expression of dihydrofolate reductase enzyme in a healthy Japanese population.

Hashiguchi M, Shimizu M, Takeuchi O, Hayashi T, Inoue S, Tanaka T, Tsuru T, Irie S, Kurokawa T, Mochizuki M*.

Jpn J Clin Pharmacol Ther 44(3)   185-192 2013年06月

研究論文（学術雑誌）, 共著, 査読有り

Claims-based definition of death in Japanese claims database: validity and implications.

N Ooba, S Setoguchi, T Ando, T Sato, T Yamaguchi, Mayumi Mochizuki, Kiyoshi Kubota

PLoS One 8 （ 5 ） e66116 2013年05月

研究論文（学術雑誌）, 共著, 査読有り

一般用医薬品の添付文書理解度調査法の開発、ー理解度への影響因子の検討ー.

橋口正行、金子梨沙、保坂藍、植田恵子、小寺典子、中村眞弓、榊原幹夫、黒川達夫、望月眞弓.

医薬品情報学 14(4)   144-160 2013年03月

研究論文（学術雑誌）, 共著, 査読有り

Willingness to pay for angiotensin-converting enzyme inhibitors as self-medication for the primary prevention of stroke in Japan.

Hashiguchi M, Watanabe E, Chiyoda T, Irie S, Kurokawa T, Mochizuki M*.

Jpn J Clin Pharmacol Ther 44(1)   29-36. 2013年01月

研究論文（学術雑誌）, 共著, 査読有り

Factors Affecting the Timing of Signal Detection of Adverse Drug Reactions

望月 眞弓

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 21   227 - 227 2012年08月

研究論文（研究会，シンポジウム資料等）, 共著,  ISSN  1053-8569

日本医薬品情報学会と医薬品情報専門薬剤師.

望月眞弓.

都薬雑誌 （東京都薬剤師会）  34(4)   2-3 2012年04月

単著

Clinical outcome in Japanese elderly patients with non-valvular atrial fibrillation taking warfarin: A single-center observational study.

Naganuma M, Shiga T, Sato K, Murasaki K, Hashiguchi M, Mochizuki M, Hagiwara N.

Thromb Res 130   21-26 2012年01月

研究論文（学術雑誌）, 共著, 査読有り

薬系大学におけるOTC医薬品教育の現状調査.

信野明美, 井澤美苗, 望月眞弓, 中島恵美*.

Jpn J Drug Inform 12(4)   163-167 2011年05月

研究論文（学術雑誌）, 共著, 査読有り

I度高血圧患者の脳卒中予防におけるアンジオテンシン変換酵素阻害薬のOver-the-counter (OTC)薬化を想定した薬剤経済学的評価.

内倉 健, 横井伸至, 橋口正行, 望月眞弓*.

薬学雑誌 131(4)   571-580. 2011年04月

研究論文（学術雑誌）, 共著, 査読有り

A double-blind, randomized clinical trial of a herbal extract energy drink in healthy young adults.

Itoh H, Isawa M, Nishimura T, Tomi M, Shimada H, Mochizuki M, Nakashima E*.

Jpn J Pharm Health Care Sci 36(12)   847-854 2010年12月

研究論文（学術雑誌）, 共著, 査読有り

ACE阻害薬使用による高カリウム血症・血中カリウム上昇の関連要因の検討.

細田眞理, 藤田利治, 橋口正行, 藤井陽介, 望月眞弓.

薬剤疫学 15(2)   49-59 2010年12月

研究論文（学術雑誌）, 共著, 査読有り

Willingness to Pay for Over-the-counter Pravastatin in Self-medication for the Primary Prevention of Myocardial Infraction.

Hashiguchi M,Matsumoto R,Watanabe N,Mochizuki M*.

Jpn J Pharmacoepidemiol 15(1)   1-9 2010年06月

研究論文（学術雑誌）, 共著, 査読有り

Interprofessional education at the Keio University Faculty of Pharmacy

望月 眞弓

Advanced Initiatives in Interprofessional Education in Japan: Japan Interprofessional Working and Education Network    57 - 63 2010年01月

研究論文（学術雑誌）

• Access to Document (DOI)

イリノテカン塩酸塩を含む化学療法施行時における排便コントロールが副作用に及ぼす影響.

渡辺和美, 高野沙織, 望月眞弓, 西澤健司, 菅紀子.

日本病院薬剤師会雑誌 45(11)   1509-1512 2009年11月

研究論文（学術雑誌）, 共著, 査読有り

Impact of community pharmacists advocating immunization on influenza vaccination rates among the eldery.

Usami T, Hashiguchi M, Kouhara T, Ishii A, Nagata T, Mochizuki M*.

YAKUGAKU ZASSHI 129(9)   1063-8 2009年09月

研究論文（学術雑誌）, 共著, 査読有り

Erythrocyte methotrexate-polyglutamate assay using the fluorescence polarization immunoassay technique: Application to the monitoring of patients with rheumatoid arthritis.

Inoue S, Hashiguchi M, Kawai S, Mochizuki M*.

YAKUGAKU ZASSHI 129(8)   1001-5 2009年08月

研究論文（学術雑誌）, 共著, 査読有り

Preliminary study to identify the predictive factors for the response to methotrexate therapy in patients with rheumatoid arthritis.

Inoue S, Hashiguchi M, Takagi K, Kawai S, Mochizuki M*.

YAKUGAKU ZASSHI 129(7)   843-9 2009年07月

研究論文（学術雑誌）, 共著, 査読有り

一般用医薬品の外箱情報の記載状況に関する調査.

橋口正行 , 青木愛 , 宇佐美孝 , 望月眞弓.

医薬品情報学 11(1)   16-23 2009年07月

研究論文（学術雑誌）, 共著, 査読有り

進行再発非小細胞肺がんにおけるCarboplatin and Weekly Paclitaxel併用療法とDocetaxel単剤療法の薬剤経済学的比較検討.

伊勢雄也, 片山志郎, 佐藤亜由美, 望月眞弓.

日本医科大学医学会雑誌 （日本医科大学）  4 （ 4 ） 257 2008年10月

研究論文（学術雑誌）, 共著

メトトレキサートによる関節リウマチ個別化療法の確立のための臨床薬理学的研究.

橋口正行, 井上幸恵, 田中孝典, 高木賢治, 川合眞一, 望月眞弓.

臨床薬理の進歩 2008   2008 2008年07月

研究論文（研究会，シンポジウム資料等）, 共著, 査読有り

転移性大腸がんに対するFOLFOX6およびmodified FOLFOX6療法での有害事象発生率の後ろ向き検討.

橋本浩伸, 篠原梨絵, 加藤裕久, 望月眞弓, 島田安博, 北條泰輔, 山本弘史.

日本病院薬剤師会雑誌 44(5)   726-730 2008年05月

研究論文（学術雑誌）, 共著, 査読有り

新しい一般用医薬品販売制度.

望月眞弓.

医薬品情報学 （/日本医薬品情報学会）  10 （ 1 ） 6-11 2008年05月

研究論文（学術雑誌）, 単著, 査読有り

日本におけるNSAID誘発性胃潰瘍に対する消化性潰瘍治療薬の費用比較分析.

橋口正行、山内暢晃、内倉健、望月眞弓*.

YAKUGAKU ZASSHI 128 （ 4 ） 585-594 2008年01月

研究論文（学術雑誌）, 共著, 査読有り

医療機関受診前の一般用医薬品の使用実態に関する調査研究〜消化器症状、頭痛での検討〜.

齋藤充、宇佐美 孝、橋口正行、末永美由紀、望月眞弓*.

医薬品情報学 9 （ 3 ） 184-189 2007年11月

研究論文（学術雑誌）, 共著, 査読有り

Use of over the counter medicines by patients with the common cold symptoms in Japan.

Usami T, Hashiguchi M, Suenaga M, Mochizuki M*.

Jpn J Drug Informatics 9 （ 2 ） 109-113 2007年09月

研究論文（学術雑誌）, 共著, 査読有り

医薬品副作用学—薬剤の安全使用アップデート—1.副作用総論(副作用重篤度分類).

橋口正行, 望月眞弓.

日本臨床 （東京/日本臨床社）  65 （ 増刊号8 ） 73-80 2007年08月

研究論文（学術雑誌）, 共著

医薬品副作用学—薬剤の安全使用アップデート—1.副作用総論(副作用・感染症報告制度).

橋口正行, 望月眞弓.

日本臨床 （東京/日本臨床社）  65 （ 増刊号8 ） 67-72 2007年08月

研究論文（学術雑誌）, 共著

医療機関受診前の一般用医薬品の使用実態に関する調査研究～消化器症状、頭痛での検討～.

齋藤充、宇佐美 孝、橋口正行、末永美由紀、望月眞弓*.

医薬品情報学 9(3)   184-189 2007年06月

研究論文（学術雑誌）, 共著, 査読有り

Use of over the counter medicines by patients with the common cold symptoms in Japan.

Usami T, Hashiguchi M, Suenaga, M Mochizuki M*.

Jpn J Drug Informatics 9(2)   109-113 2007年04月

研究論文（学術雑誌）, 共著, 査読有り

Pharmacogenetic study of methylenetetrahydrofolate reductase and thymidylate synthase in Japanese and assessment of ethnic and gender differences.

Inoue S, Hashiguchi M, Chiyoda T, Sunami Y, Tanaka T, Mochizuki M*.

Pharmacogenomics 8(1)   41-47 2007年01月

研究論文（学術雑誌）, 共著, 査読有り

一歩進んだ医薬品情報の活用 治療に関する項目(4).

橋口正行, 望月眞弓.

調剤と情報 （/じほう）  12(12)   1555-1559 2006年11月

研究論文（学術雑誌）, 共著

一歩進んだ医薬品情報の活用 治療に関する項目(3).

橋口正行, 望月眞弓.

調剤と情報,2006 （/じほう）  12(11)   1437-1441 2006年10月

研究論文（学術雑誌）, 共著

一歩進んだ医薬品情報の活用 治療に関する項目(2).

橋口正行, 望月眞弓.

調剤と情報 （/じほう）  12(10)   1133-1136 2006年09月

研究論文（学術雑誌）, 共著

薬剤費患者一部自己負担の薬剤供給に関する影響.

大日康史、菅原民枝、池田俊也、庭田聖子、望月眞弓.

医療と社会 15(3)   15(3) 2006年08月

研究論文（学術雑誌）, 共著, 査読有り

一歩進んだ医薬品情報の活用 医薬品情報を収集する(2).

橋口正行,望月眞弓.

調剤と情報 （/じほう）  12(2)   67-73 2006年02月

研究論文（学術雑誌）, 共著

日本における市中肺炎患者に対するクリティカルパス導入による抗生物質の投与日数及び費用に対する影響.

内倉健、橋口正行、鈴木幸男、竹下啓、土本寛治、池田俊也、坂巻弘之、清水喜八郎、安部直、望月眞弓*.

YAKUGAKU ZASSHI 125   125 2005年06月

研究論文（学術雑誌）, 共著, 査読有り

医療機関受診前の一般用医薬品の使用実態に関する調査研究(1).

宇佐美 孝、橋口正行、望月眞弓*.

医薬品情報学 7   7 2005年04月

研究論文（学術雑誌）, 共著, 査読有り

Comparison of cilostazol and ticlopidine coadministered with aspirin for long-term efficacy and safety after coronary stenting; a meta-analysis.

Hashiguchi M, Ohno K, Kishino S, Mochizuki M, Shiga T.

Jpn J Clin Pharmacol Ther 36(2)   69-79 2005年03月

研究論文（学術雑誌）, 共著, 査読有り

Classification of Pharmaceutical Services from the Viewpoint of Patient Satisfaction/Dissatisfaction.

Hayashi S, Hayase T, Mochizuki M, Hashiguchi M, Takeuchi K.

YAKUGAKU ZASSHI 124   159-168 2005年01月

研究論文（学術雑誌）, 共著, 査読有り

Evidenceに基づいた健康食品の情報データベース作成とその評価.

葉室聡子, 鳥居友紀子, 橋口正行, 望月眞弓*.

医薬品情報学 6   6 2004年11月

研究論文（研究会，シンポジウム資料等）, 共著, 査読有り

ニコレット&reg;による禁煙達成に及ぼす保険薬局薬剤師の禁煙指導の有効性に関するランダム化群間比較調査研究-禁煙開始3ヵ月後での評価-.

望月眞弓*, 初谷真咲, 六條恵美子, 有田悦子, 橋口正行, 清水直容, 竹内正弘, 山本信夫, 秋葉保次.

YAKUGAKU ZASSHI 124   124 2004年09月

研究論文（学術雑誌）, 共著, 査読有り

Comparison of cilostazol and ticlopidine for one-month effectiveness and safety after elective coronary stenting &#8211; meta-analysis.

Hashiguchi M, Ohno K, Nakazawa R, Kishino S, Mochizuki M, Shiga T.

Cardiovascular Drug and Therapy 18   213-219 2004年01月

研究論文（学術雑誌）, 共著, 査読有り

介護者のための医薬品情報集の作成(その3) 家族のための大衆薬情報集.

井澤美苗, 木津純子, 望月眞弓, 望月正隆, 中島恵美.

医薬品情報学 5(1)   5(1) 2003年05月

研究論文（学術雑誌）, 共著, 査読有り

Sex difference in the effect of aspirin on the prevention of coronary heart disease: A gender-based meta-analysis of randomized placebo-controlled, double-blind trials.

Kamijima Y, Mochizuki M, Yamagata S, Satoh N, Ohata T, Uruno T, Ueda S.

JJDI 4   151-157 2002年05月

研究論文（学術雑誌）, 共著, 査読有り

インターネットを介した症例サマリーデータベースの構築とその臨床薬学教育における意義.

阿部正樹, 大林恭子, 今野裕子, 山本康次郎, 片岡聡, 望月眞弓, 上田志朗, 大江和彦, 橋本源一, 堀内龍也.

YAKUGAKU ZASSHI 122   122 2002年04月

研究論文（学術雑誌）, 共著, 査読有り

医療活動におけるインターネット利用に関するパイロット・スタディ:薬剤師を対象としたアンケート調査の結果報告.

寺島朝子, 町田絵里, 山形真一, 佐藤信範, 望月眞弓, 上田志朗.

薬学雑誌 122(6)   122(6) 2002年03月

研究論文（学術雑誌）, 共著, 査読有り

医療関連情報の検索におけるインターネットの利便性およびWebサイトの信頼性に関する調査 -高齢心筋梗塞患者に対する薬物治療について-.

寺島朝子, 町田絵里, 山形真一, 佐藤信範, 望月眞弓, 上田志朗.

医療情報学 21(6)   21(6) 2002年02月

研究論文（学術雑誌）, 共著, 査読有り

Developing and integrating an adverse drug reaction reporting system with the hospital information system.

Kataoka S, Ohe K, Mochizuki M, Ueda S.

Yakugaku Zasshi 122   113-116 2002年01月

研究論文（学術雑誌）, 共著, 査読有り

Comparative studies of dialyzability of levofloxacin and amlodipine using in vitro dialysis system with three different types of dialyzers

望月 眞弓

Journal of Health Science 45 （ 5 ） 271 - 275 1999年01月

研究論文（学術雑誌）